1 Min Read
Feb 13 (Reuters) - X T L Biopharmaceuticals Ltd
* X T L Biopharmaceuticals - expands clinical advisory board with two experts in rheumatology to support Phase II study of HCDR1 in Sjogren’s syndrome Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.